Keyword: Patrick Mahaffey

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.

Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.

Clovis may be the middle child among next-gen ovarian cancer meds, but it’s hoping new data will open the therapy to a wave of new patients.